Dissecting Variation in Biomass Conversion Factors across China’s Forests: Implications for Biomass and Carbon Accounting

Por Luo, Yunjian, Zhang, Xiaoquan, Wang, Xiaoke, Ren, Yin
Publicado em 2014

Overexpression of NtDOG1L-T Improves Heat Stress Tolerance by Modulation of Antioxidant Capability and Defense-, Heat-, and ABA-Related Gene Expression in Tobacco

Por Dai, Xiaoyan, Wang, Yingfeng, Chen, Yanchun, Li, Hongchen, Xu, Shixiao, Yang, Tiezhao, Zhang, Xiaoquan, Su, Xinhong, Xia, Zongliang
Publicado no Front Plant Sci (2020)

Characterization and functional analysis of phytoene synthase gene family in tobacco

Por Wang, Zhaojun, Zhang, Lin, Dong, Chen, Guo, Jinggong, Jin, Lifeng, Wei, Pan, Li, Feng, Zhang, Xiaoquan, Wang, Ran
Publicado no BMC Plant Biol (2021)

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

Por Gupta, Neeraj, Zhang, Steven, Pusalkar, Sandeepraj, Plesescu, Mihaela, Chowdhury, Swapan, Hanley, Michael J., Wang, Bingxia, Xia, Cindy, Zhang, Xiaoquan, Venkatakrishnan, Karthik, Shepard, Dale R.
Publicado no Invest New Drugs (2017)

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

Por Gupta, Neeraj, Hanley, Michael J., Harvey, R. Donald, Badros, Ashraf, Lipe, Brea, Kukreti, Vishal, Berdeja, Jesus, Yang, Huyuan, Hui, Ai‐Min, Qian, Mark, Zhang, Xiaoquan, Venkatakrishnan, Karthik, Chari, Ajai
Publicado no Br J Haematol (2016)

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanc...

Por Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Bessudo, Alberto, Rasco, Drew W., Sharma, Sunil, O'Neil, Bert H., Wang, Bingxia, Liu, Guohui, Ke, Alice, Patel, Chirag, Rowland Yeo, Karen, Xia, Cindy, Zhang, Xiaoquan, Esseltine, Dixie‐Lee, Nemunaitis, John
Publicado no J Clin Pharmacol (2017)

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation s...

Por Hou, Jian, Jin, Jie, Xu, Yan, Wu, Depei, Ke, Xiaoyan, Zhou, Daobin, Lu, Jin, Du, Xin, Chen, Xiequn, Li, Junmin, Liu, Jing, Gupta, Neeraj, Hanley, Michael J., Li, Hongmei, Hua, Zhaowei, Wang, Bingxia, Zhang, Xiaoquan, Wang, Hui, van de Velde, Helgi, Richardson, Paul G., Moreau, Philippe
Publicado no J Hematol Oncol (2017)